Adaptive Biotechnologies

ADPT

Market cap $2.17B

SEATTLE, April 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2026 after market close on Tuesday, May 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

The President and COO of Adaptive Biotechnologies Corporation reported the sale of 38,120 shares for about $554,000, based on a weighted average transaction price of $14.53 per share across April 1–2, 2026. This sale represented 7.85% of Rubinstein's direct Common Stock holdings, reducing her direct position to 447,202 shares post-transaction.

81,342 shares were sold for a total value of ~$1.21 million across multiple transactions from March 6 to March 10, 2026. The sale represented 11.22% of Rubinstein's direct holdings, reducing her direct ownership to 643,471 shares post-transaction.

An executive at Adaptive Biotechnologies reported the sale of 179,703 shares for about $2.37 million, based on a weighted average price of around $13.21 per share during March 11–13, 2026. This sale was executed directly and arose from the exercise and immediate sale of option-derived Common Stock; no indirect (e.g.

Francis Lo, Chief People Officer at Adaptive Biotechnologies (ADPT +0.00%), reported the sale of a combined 68,667 shares of common stock across two transactions in early March 2026, as disclosed in a pair of SEC Form 4 filings.

Adaptive Biotechnologies (ADPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Adaptive Biotechnologies Corporation (ADPT) Q4 2025 Earnings Call Transcript

While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.23 per share a year ago.

SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2025.